24/7 Market News Snapshot 07 July, 2025 – Cyclacel Pharmaceuticals, Inc (NASDAQ:CYCC)

July 7, 2025

DENVER, Colo., 07 July, 2025 (www.247marketnews.com) – (NASDAQ:CYCC) are discussed in this article.
Cyclacel Pharmaceuticals, Inc. (CYCC) has seen a notable increase in its stock value, beginning at $1.094 and rising to $3.915, marking a significant gain of approximately 10.59% from a previous close of $3.540. This surge accompanies elevated trading activity, with a current volume of 4.01 million shares, indicating substantial investor engagement and potential for reaccumulation. Traders are advised to monitor support levels around $3.540, as a breakout above recent highs may pave the way for further advances in share price, making CYCC a compelling stock for investors in the biotechnology sector.

In tandem with its stock performance, Cyclacel is making significant progress in addressing fibrolamellar hepatocellular carcinoma (FLC), a rare and aggressive liver cancer that primarily affects younger populations. Recent research published in the peer-reviewed journal *Gut* has identified a critical association between the DNAJ-PKAc fusion oncoprotein, known to accelerate FLC progression, and an increased sensitivity to plogosertib, a novel Polo-like Kinase 1 (PLK1) inhibitor developed by Cyclacel.

This study reveals that the DNAJ-PKAc fusion elevates the susceptibility of FLC cells to PLK1 inhibitors, suggesting a promising therapeutic strategy. Notably, plogosertib has shown potential in inhibiting the growth of FLC tumors while sparing normal liver cells, warranting further clinical investigation. Given the absence of approved treatments for FLC and its challenging prognosis—characterized by a mere 30% five-year survival rate—the findings present a crucial development in the quest for efficacious therapies.

As Cyclacel continues to explore innovative treatment options through rigorous scientific research, the company underscores its dedication to transforming cancer care and improving patient outcomes amidst a landscape that yearns for impactful solutions.

Related news for (CYCC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.